|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8133893||ANGELINI PHARMA||Trazodone and trazodone hydrochloride in purified form|| |
(5 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7829120||ANGELINI PHARMA||Trazodone composition for once a day administration|| |
(3 years from now)
Oleptro is owned by Angelini Pharma.
Oleptro contains Trazodone Hydrochloride.
Oleptro has a total of 2 drug patents out of which 0 drug patents have expired.
Oleptro was authorised for market use on 02 February, 2010.
Oleptro is available in tablet, extended release;oral dosage forms.
Oleptro can be used as method of treating depression.
The generics of Oleptro are possible to be released after 13 March, 2029.
Market Authorisation Date: 02 February, 2010
Treatment: Method of treating depression
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic